Loading…
Loading…
Kimberly-Clark is nearing completion of its $48.7bn acquisition of Kenvue, with key regulatory approvals secured. Current earnings cover the dividend at 69%, but combined FCF only covers it at about 1.07x before $2.5bn in integration costs. Kenvue's Tylenol litigation was revived in July, and they have no reserve for it. A settlement of Zantac-size would be at $2bn and cost $2.50 per share.
Clean beauty, innovation and digital shopping are reshaping the industry. Explore how ELF, EL and ULTA are adapting to changing consumer preferences.
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its third quarter 2026 financial results before the market opens on October 30, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a ce.
Every month, we screen for dividend growth stocks that have relatively higher yields. While higher yields can often mean relatively higher risk, depending on the sector, we also include consistency and safety dividend quant grades in the process. We then take a quick look at the top 5 that come up in the screening to see if they are potentially worth pursuing for deeper research and due diligence.
The European Commission—the EU's executive arm—said that the sale fully addresses officials' earlier concerns that the deal could hinder competition in tampon markets in Czechia, Estonia, and Slovakia.
DALLAS, Oct. 13, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today that the requisite number of consents have been received to adopt certain proposed amendments (the "Amendments") with respect to all outstanding notes of Kenvue Inc. (NYSE: KVUE) ("Kenvue"). The results are based on (i) early tenders in the offers to exchange (each an "Exchange Offer" and, collectively, the "Exchange Offers") any and all outstanding notes (the "Kenvue Notes") issued by Kenvue for up to $7,000,000,000 aggregate principal amount of new notes to be issued by Kimberly-Clark (the "Kimberly-Clark Notes") and cash and (ii) related consent solicitations (each, a "Consent Solicitation" and, collectively, the "Consent Solicitations") being made by Kimberly-Clark on behalf of Kenvue to adopt the Amendments to the indenture (the "Kenvue Indenture") governing the Kenvue Notes.
While nervous investors obsess over a handful of tech giants propping up the whole market, one portfolio manager keeps funneling fresh cash into the brands sitting in every American medicine cabinet, and the reasoning might make you rethink your own